Evidence map›Paper›PMID 25551178›Full record

Trial reportBMC infectious diseases2014

The microbiology of impetigo in indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus, scabies, and nasal carriage.

Asha C Bowen, Steven Y C Tong, Mark D Chatfield, Jonathan R Carapetis

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC infectious diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.

  1. Pooled it
  2. Berrembi Jarragboo-Boorroo Wajawoorroo Men'Gawoom Gijam (Gija Healthy Skin Story): Two-Way Learning for Healthy Skin.Health promotion journal of Australia : official journal of Australian Association of Health Promotion Professionals · 2025
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Scabies.Nature reviews. Disease primers · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Microbe Interactions within the Skin Microbiome.Antibiotics (Basel, Switzerland) · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Asha C BowenMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. asha.bowen@menzies.edu.au.
Steven Y C TongMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia. steven.tong@menzies.edu.au.
Mark D ChatfieldTelethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia. mark.chatfield@menzies.edu.au.
Jonathan R CarapetisPrincess Margaret Hospital for Children, Perth, Western Australia, Australia. jonathan.carapetis@telethonkids.org.au.
The Kids Research Institute Australia · AUCharles Darwin University · AUMenzies School of Health Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImpetigo is caused by both Streptococcus pyogenes and Staphylococcus aureus; the relative contributions of each have been reported to fluctuate with time and region. While S. aureus is reportedly on the increase in most industrialised settings, S. pyogenes is still thought to drive impetigo in endemic, tropical regions. However, few studies have utilised high quality microbiological culture methods to confirm this assumption. We report the prevalence and antimicrobial resistance of impetigo pathogens recovered in a randomised, controlled trial of impetigo treatment conducted in remote Indigenous communities of northern Australia.

methodsEach child had one or two sores, and the anterior nares, swabbed. All swabs were transported in skim milk tryptone glucose glycogen broth and frozen at -70°C, until plated on horse blood agar. S. aureus and S. pyogenes were confirmed with latex agglutination.

resultsFrom 508 children, we collected 872 swabs of sores and 504 swabs from the anterior nares prior to commencement of antibiotic therapy. S. pyogenes and S. aureus were identified together in 503/872 (58%) of sores; with an additional 207/872 (24%) sores having S. pyogenes and 81/872 (9%) S. aureus, in isolation. Skin sore swabs taken during episodes with a concurrent diagnosis of scabies were more likely to culture S. pyogenes (OR 2.2, 95% CI 1.1 - 4.4, p = 0.03). Eighteen percent of children had nasal carriage of skin pathogens. There was no association between the presence of S. aureus in the nose and skin. Methicillin-resistance was detected in 15% of children who cultured S. aureus from either a sore or their nose. There was no association found between the severity of impetigo and the detection of a skin pathogen.

conclusionsS. pyogenes remains the principal pathogen in tropical impetigo; the relatively high contribution of S. aureus as a co-pathogen has also been confirmed. Children with scabies were more likely to have S. pyogenes detected. While clearance of S. pyogenes is the key determinant of treatment efficacy, co-infection with S. aureus warrants consideration of treatment options that are effective against both pathogens where impetigo is severe and prevalent.

trial registrationThis trial is registered; ACTRN12609000858291 .

Indexed as

AdolescentAustraliaCarrier StateChildChild, PreschoolCoinfectionFemaleHumansImpetigoInfantMaleMethicillin ResistanceNosePopulation GroupsPrevalenceRespiratory Tract Infections

Identifiers

PMID25551178
PMCPMC4299569
OpenAlexW2008372760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.